Líffræðifélag Íslands - biologia.is
Líffræðiráðstefnan 2023
Höfundar / Authors: Jenny Lorena Molina Estupiñan(1,2), Poorya Foroutan Pajoohian(1,2), Jan Holmgren(3) Stefanía P. Bjarnarson(1,2), Ingileif Jónsdóttir(1) Auður Anna Aradóttir Pind(1,2)
Starfsvettvangur / Affiliations: 1. Faculty of Medicine, School of Health Sciences, University of Iceland, 2. Department of Immunology, Landspitali, the National University Hospital of Iceland, Iceland, 3. University of Gothenburg, Dept. Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, and University of Gothenburg Vaccine Research Institute (GUVAX), Sweden
Kynnir / Presenter: Jenny Lorena Molina Estupinan
Childhood vaccinations give long term protection against many infectious diseases, but multiple vaccinations are required. In many cases, vaccine demand exceeds vaccine production capacity. Adjuvants can enhance magnitude and duration of immune responses and may reduce vaccine dose needed to induce protective immunity, allowing dose sparing and cost savings. In this study we assessed the dose sparing effects of the adjuvants dmLT, mmCT and alum on neonatal antibody response to a pneumococcal conjugate vaccine Pn1-CRM197, and mmCT and alum to an influenza HA vaccine, following s.c. immunization with fractional doses of the vaccines with adjuvants and compared with a full dose of vaccines without adjuvants. Antibody levels of neonatal mice immunized with a full dose of Pn1-CRM197 were low. Inclusion of mmCT or dmLT enhanced Pn1-specific IgG elicited by fractional doses of Pn1-CRM197 inducing protective levels against pneumococcal infection in neonatal mice, where inclusion of mmCT provided 8-fold dose sparing of the vaccine and dmLT 5.3-fold. Mice immunized with a full dose of HA alone elicited high HA-specific IgG levels, comparable with fractional doses of the HA vaccine with mmCT, where inclusion of mmCT provided 4-fold dose sparing. Alum did not induce dose sparing with either vaccine. Thus, we conclude that the adjuvants dmLT and mmCT are good candidates for dose sparing and could be used at times when vaccine demand exceeds vaccine production capacity.